Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

0.8112 +0.0051 (+0.63%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 23, 2024

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

August 21, 2024

Expansion of leadership team to strengthen global clinical expertise

From Tempest Therapeutics

Via GlobeNewswire

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? ↗

August 15, 2024

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...

Via Benzinga

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

August 15, 2024

From Tempest Therapeutics

Via GlobeNewswire

TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024 ↗

August 09, 2024

TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

August 08, 2024

From Tempest Therapeutics

Via GlobeNewswire

$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

July 05, 2024

Via Benzinga

Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher ↗

June 20, 2024

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 20, 2024

Via Benzinga

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 20, 2024

Via Benzinga

Gold Rises 1%; Accenture Shares Surge After Q3 Results ↗

June 20, 2024

Via Benzinga

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday? ↗

June 20, 2024

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...

Via Benzinga

Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today? ↗

June 20, 2024

NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.

Via InvestorPlace

Why Is Avrobio (AVRO) Stock Moving Today? ↗

June 20, 2024

Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.

Via InvestorPlace

Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

June 20, 2024

Via Benzinga

Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? ↗

June 20, 2024

Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 20, 2024

Via Benzinga

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

June 20, 2024

From Tempest Therapeutics

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

June 20, 2024

Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 19, 2024

Via Benzinga

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

June 18, 2024

Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 07, 2024

From Tempest Therapeutics

Via GlobeNewswire

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

Tempest to Participate in Upcoming Investor Conferences

May 21, 2024

From Tempest Therapeutics

Via GlobeNewswire

TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024 ↗

May 09, 2024

TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 26, 2024

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

April 09, 2024

From Tempest Therapeutics

Via GlobeNewswire

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

April 05, 2024

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.

Via Benzinga

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

April 04, 2024

From Tempest Therapeutics

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.